Literature DB >> 12527718

Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules.

So Ya Paik1, Young Nyun Park, Hoguen Kim, Chanil Park.   

Abstract

In this study we analyzed by immunohistochemistry the expression of TGF-beta1 protein and TGF-beta receptors I and II in 4 low-grade dysplastic nodules, 2 high-grade dysplastic nodules, 6 early, 22 small, and 62 advanced hepatocellular carcinomas. The expression of TGF-beta1 protein by hepatocytes was decreased in advanced hepatocellular carcinoma compared with small or early hepatocellular carcinoma(P < .05). Frequent and intense staining of TGF-beta1 protein was noted in the sinusoidal endothelium of advanced hepatocellular carcinomas despite of its decreased staining in hepatocellular carcinoma cells. Reduced expression of TGF-beta receptors I and II compared with surrounding nontumorous tissue were noted from the early hepatocellular carcinoma stage suggesting that down-regulation of TGF-beta receptors is correlated with progression from premalignant to malignant phenotype. Reduced expression of both TGF-beta1 and TGF-beta receptor II in neoplastic hepatocytes were also significantly correlated with increased tumor size and increased proliferative activity(P < .05). These findings suggest that during hepatocarcinogenesis, the inhibitory effects of TGF-beta1 protein on hepatocellular carcinoma cells is outweighed by its effects on stromal elements, which, overall, contributes indirectly to a tumor growth stimulatory environment. Also, the growth-inhibitory effects of TGF-beta1 may have been further negated by reduced TGF-beta receptors on hepatocellular carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527718     DOI: 10.1097/01.MP.0000047308.03300.9C

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Decorin inhibits the proliferation of HepG2 cells by elevating the expression of transforming growth factor-β receptor II.

Authors:  Yanfeng Liu; Xuesong Wang; Zhaohui Wang; Wenbo Ju; Dawei Wang
Journal:  Exp Ther Med       Date:  2016-08-04       Impact factor: 2.447

2.  Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.

Authors:  D W Chan; V W S Liu; R M Y To; P M Chiu; W Y W Lee; K M Yao; A N Y Cheung; H Y S Ngan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

3.  Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients.

Authors:  Rola M Farid; Riham M Abu-Zeid; Ahmed El-Tawil
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features.

Authors:  Osmar Damasceno Ribeiro; Nathalie Henriques Silva Canedo; Vera Lucia Pannain
Journal:  Clinics (Sao Paulo)       Date:  2016-11-01       Impact factor: 2.365

Review 5.  Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy.

Authors:  Maryam Tahmasebi Birgani; Vinicio Carloni
Journal:  Int J Mol Sci       Date:  2017-02-14       Impact factor: 5.923

6.  Hepatic stellate cells - from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology.

Authors:  Rada Teodora Sufleţel; Carmen Stanca Melincovici; Bogdan Alexandru Gheban; Zaharie Toader; Carmen Mihaela Mihu
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

7.  Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest.

Authors:  Sharon Sheahan; Christopher O Bellamy; Donald R Dunbar; David J Harrison; Sandrine Prost
Journal:  BMC Cancer       Date:  2007-11-19       Impact factor: 4.430

8.  TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21Cip1 or Rb status.

Authors:  Sharon Sheahan; Christopher O Bellamy; Stephen N Harland; David J Harrison; Sandrine Prost
Journal:  BMC Cancer       Date:  2008-07-08       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.